Very unlikely! As a matter-of-fact expect the share price to gap up and open up at 3.71 X 3.72.
Search for article:
MLV & Co Analysts Give Threshold Pharmaceuticals a $14.50 Price Target (THLD)
This finding raises the question as to whether the prolongation of mPFS and median overall survival (mOS) reported with Threshold Pharmaceuticals’ TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in a Phase II trial would be improved if doxorubicin was replaced with aldoxorubicin.
The analysts wrote, “Recently CytRx Corp. (Nasdaq:CYTR; not covered) announced that aldoxorubicin, a tumor-targeted doxorubicin prodrug, met its primary endpoint of prolonging median progression-free survival (mPFS) in a randomized Phase IIb trial versus doxorubicin as front line therapy for advanced soft tissue sarcoma (STS). This finding raises the question as to whether the prolongation of mPFS and median overall survival (mOS) reported with Threshold Pharmaceuticals’ TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in a Phase II trial would be improved if doxorubicin was replaced with aldoxorubicin. Both drugs have now advanced into pivotal Phase III trials; TH-302 (with doxorubicin) for front line therapy and aldoxorubicin for second line therapy. Topline results for these trials are expected in 1Q:16 and mid-2016, respectively. We think both drugs have the potential of being the first new drugs to be approved for the treatment of STS in many years and to become the new standard of care. Since just about all patients with metastatic STS eventually relapse, we believe it is likely that both drugs will capture a substantial share of the market if the Phase III trials deliver positive results. We reiterate our BUY rating and $14.50 one-year price target for Threshold Pharmaceuticals, Inc.
Threshold has Partnered with Merck KGaA, Darmstadt, Germany who hasn't had much success in the past. Investors aren't thrilled with their choice. Both cytrx and threshold have a chance to provide new treatments. However, I like cytrx's chances of being more successful in the long run. Threshold already had their partnership announced. So cytrx has that potential catalyst looming if they do in fact announce a partnership in the near future. Cytrx has no debt, not sure about Threshold. I owned that company too and lost money. It would be interesting to learn how it would be even possible for Cytrx and Threshold to work together in some kind of trial. Would one company need to buy out the other? If that was the case I would expect Cytrx to buyout Threshold. Interesting how Merck KGaA, Darmstadt, Germany is only 150 miles form the new Cytrx lab in Freiburg, Germany. Hmmm!
Cytrx is going for FDA approval for Aldo and Dox as a second-line treatment not a firs-line treatment.
Doesn't the priced offering of US $500 million aggregate principal amount of 3.000 percent notes due April 1, 2025 savings more than offset the pre-tax deduction on the bottom line when they report earnings? High demand and making a deal with China even if it is at $315/tonne should help them meet the higher end of their guidance. Also, it still hasn't been announced how many tonnes of potash Belaruskali is selling to China. If they can't meet their capacity demand that puts pot in the driver seat.
I think a company like BHP can come in a buy out a company like Mosaic or Agrium. Potash Corp's market cap is too large in my opinion. But now is the time for something like this to happen. Could push prices up and Potash would benefit from big time from it. I think between now and June something big will happen in this industry.
Innovation into Biofertilizers to Drive Potassium Chloride
Leading companies such as PotashCorp have made significant investments in the brownfield potash expansion projects